Platform|API|Archive|Contact
Humanexa SignalsPharmaceutical Intelligence
Subscribe
Signals
Regulatory
  • FDA
  • EMA
  • MHRA
  • PMDA
  • Health Canada
Clinical
  • Phase I
  • Phase II
  • Phase III
  • Readouts
  • Enrollment Signals
Competitive
  • Pipeline Tracking
  • Company Moves
  • Asset Intelligence
  • Landscape Reports
Markets
  • Pricing
  • Access
  • Commercial
  • Launch Tracking
M&A Watch
  • Licensing
  • Acquisitions
  • Partnerships
  • Capital Raises
StrategyCatalystsPricing
Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

  • Regulatory
  • Clinical
  • Competitive
  • Markets
  • M&A Watch
  • Strategy
  • Catalyst Tracker

Company

  • Pricing
  • Partner with us
  • Subscribe
  • Contact
  • Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

ClinicalAnesthesiaPain ManagementTrial Update

Study on Ketamine vs Fentanyl for Pain Management in Laparoscopic Cholecystectomy

This clinical trial could significantly impact postoperative pain management protocols, potentially favoring ketamine over traditional analgesics like fentanyl. A shift in clinical practice could alter market dynamics and influence the competitive landscape for pain management solutions.

Published: June 27, 2026
Updated: June 27, 2026
Author: Humanexa Intelligence
Therapeutic area: Anesthesia / Pain Management
Asset: ketamine
Trial SummaryCLN

Phase III

Anesthesia / Pain Management

Status

Active

Signal Score

8.2

Signal assessment

Signal strength

high

Confidence level

moderate

Signalhigh
Confidencemoderate

Strategic implication

This clinical trial could significantly impact postoperative pain management protocols, potentially favoring ketamine over traditional analgesics like fentanyl. A shift in clinical practice could alter market dynamics and influence the competitive landscape for pain management solutions.

Why it matters

This clinical trial could significantly impact postoperative pain management protocols, potentially favoring ketamine over traditional analgesics like fentanyl. A shift in clinical practice could alter market dynamics and influence the competitive landscape for pain management solutions.

What changed

Trial Update

Analysis

A randomized double-blind study is comparing intraperitoneal ketamine and fentanyl as adjuvants to bupivacaine for postoperative pain control in laparoscopic cholecystectomy.

This clinical trial could significantly impact postoperative pain management protocols, potentially favoring ketamine over traditional analgesics like fentanyl. A shift in clinical practice could alter market dynamics and influence the competitive landscape for pain management solutions.

Monitor results of the trial for efficacy data and subsequent changes in clinical guidelines for postoperative pain management.

Related companies & assets

Assets

  • ketamine →
  • bupivacaine →

Sources & Humanexa intelligence

Source links

  • Study on Ketamine vs Fentanyl for Pain Management in Laparoscopic Cholecystectomy ↗

Related Humanexa pages

  • Study on Ketamine vs Fentanyl for Pain Management in Laparoscopic Cholecystectomy →

Related signals

Trial SummaryCLN

Phase III

cancer patients

Status

Active

Signal Score

6.8

Clinicalmoderate signal

Feasibility Study of RestoreMe App for Cancer Patient Nutrition and Activity

Montefiore Medical Center is conducting a feasibility study to assess the RestoreMe app for cancer patients, recruiting 150 participants.

July 3, 2026Read signal →
Trial SummaryCLN

Phase III

Oncology / Multiple Myeloma

Status

Active

Sponsor

Bristol Myers Squibb

Signal Score

8.2

Clinicalhigh signal

Bristol-Myers Squibb Compares Iberdomide to Lenalidomide in Multiple Myeloma Maintenance Therapy

A clinical trial is underway to evaluate iberdomide maintenance therapy against lenalidomide maintenance following ASCT in NDMM patients.

July 3, 2026Read signal →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.